| Title |
Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
|
|---|---|
| Published in |
Clinical Drug Investigation, November 2013
|
| DOI | 10.1007/s40261-013-0153-2 |
| Pubmed ID | |
| Authors |
Jinshan Shen, Robert Townsend, Xiaoli You, Yun Shen, Ping Zhan, Zexun Zhou, Dong Geng, Dianna Wu, Nadia McGirr, Kathleen Soucek, Elizabeth Proszynski, Janice Pursley, Eric Masson |
| Abstract |
Belatacept is a first-in-class, selective co-stimulation blocker recently approved for the prophylaxis of organ rejection in adult kidney transplant recipients. The objective of this study was to report the pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 75% |
| Netherlands | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 25% |
| Scientists | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 2% |
| Argentina | 1 | 2% |
| Unknown | 41 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 8 | 19% |
| Researcher | 8 | 19% |
| Student > Postgraduate | 5 | 12% |
| Student > Ph. D. Student | 4 | 9% |
| Other | 3 | 7% |
| Other | 3 | 7% |
| Unknown | 12 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 26% |
| Agricultural and Biological Sciences | 5 | 12% |
| Biochemistry, Genetics and Molecular Biology | 4 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 7% |
| Immunology and Microbiology | 3 | 7% |
| Other | 2 | 5% |
| Unknown | 15 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2018.
All research outputs
#12,595,605
of 22,731,677 outputs
Outputs from Clinical Drug Investigation
#605
of 959 outputs
Outputs of similar age
#103,944
of 212,426 outputs
Outputs of similar age from Clinical Drug Investigation
#10
of 12 outputs
Altmetric has tracked 22,731,677 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 959 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,426 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.